The promise is deceptively simple: a compact sensor strapped to the wrist that detects when a stroke survivor attempts to move, then pulses a vibration the instant muscle activation occurs. The hope—and this is where the science gets delicate—is that repeated feedback might coax the damaged neural pathways back to life.
Neubond, a medtech spinout from Imperial College London, has just secured £1.5 million in seed funding to find out whether that hope can scale beyond the lab. The round, announced recently, was led by Tokyo's Waseda University Ventures (WUV), which says this marks the Japanese firm's first foray into UK deeptech. SFC Capital and New Wave Ventures, both UK investors, joined.
For Neubond, the funding unlocks the next critical phase: pushing toward MHRA medical device certification while supporting feasibility studies at Charing Cross Hospital. It's a typical inflection point for early-stage medtech companies—where promising pilot data meets the unforgiving machinery of regulatory approval.
Closing the Loop
The technology hinges on what engineers call a closed-loop system. Neubond's device senses muscle activation with what the company describes as high precision, then delivers immediate vibrotactile feedback—essentially, a carefully timed buzz. The aim is to rebuild the connection between movement intent and muscle response, a link often severed or scrambled after stroke.
A paired app gives clinicians the ability to set exercise programmes and track adherence remotely. Patients, meanwhile, can monitor their own progress through a companion interface, logging exercise counts and contraction quality.
The company has reported—though not yet in peer-reviewed form—a 15-patient pilot showing a 30 percent improvement in range of motion after one month. The sample size is small enough to warrant caution. A feasibility study now underway at Charing Cross Hospital is designed to inform the design of future randomized controlled trials—the gold standard that investors and regulators will eventually demand.
Academic Roots, Industrial Ambitions
Dr. Patrick Sagastegui Alva and Jumpei Kashiwakura co-founded Neubond inside Imperial's Department of Bioengineering, working alongside Prof. Dario Farina, who chairs the university's Neurorehabilitation Engineering group. Kashiwakura brought mechanical and bioengineering expertise honed at Toyota; Sagastegui Alva's background spans electrical and bioengineering disciplines.
Incorporated in February 2024, the company has already pulled in more than £720,000 in non-dilutive grants as of early 2025, including a European Research Council Proof-of-Concept award. It also won the Health & Wellbeing track of Imperial's Venture Catalyst Challenge last year and participated in Innovate UK's ICURe programme—a series of checkboxes familiar to anyone tracking the UK's academic spinout ecosystem.
A Cross-Border Calculation
Waseda University Ventures' decision to lead marks a bet on UK deeptech from an investor better known for backing Japanese startups. Tetsuya (Ted) Yamamoto, a general partner at WUV, joined Neubond's board on June 9, according to UK Companies House filings—a signal that the firm sees strategic value beyond simple portfolio diversification.
SFC Capital, an active player in the UK's seed and SEIS landscape, and New Wave Ventures, a privately-held firm with healthtech holdings, rounded out the syndicate.
The Long Road Ahead
The £1.5 million will fund product development, safety testing, and the regulatory submissions required for MHRA certification. The feasibility work at Charing Cross will shape trial design—and, crucially, help Neubond refine its value proposition for payers and health systems.
The market opportunity is undeniably vast. More than 13 million strokes occur globally each year, with an estimated economic burden exceeding $890 billion when you factor in healthcare costs and lost productivity. Effective, scalable rehabilitation tools remain scarce, particularly for patients who can't access regular in-person therapy.
Whether Neubond's approach can deliver clinical efficacy at scale remains an open question. The technology is elegant; the regulatory pathway, less so. For now, the company has bought itself runway to answer the hardest questions—the ones that separate promising prototypes from devices that actually reach patients.
